In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Subspecialty communities

The ESC comprises 28 cardiovascular subspecialty communities covering the full spectrum of cardiology.
They include 7 Associations, 15 Working Groups and 6 Councils, enabling us to provide in-depth, expert knowledge to all cardiovascular clinicians and researchers.


ACNAP-Logo-official.png
ACVC-logo-official.png
EAPC-Logo-official.png
EACVI-Logo-official.png
EAPCI-Logo-official.png
EHRA-Logo-official.png
HFA-Logo-official.png
ESC-Councils-Logo-official.png
ESC-WG-Logo-official.png


 

Membership Offer

Discover our offer

Join the leading network of experts in cardiac care

  • Be part of a multi-disciplinary network
  • Gain exclusive knowledge and expertise
  • Access exclusive resources for free or at preferred price
  • Build the future of your association

Communities' Upcoming Events

  • March 2024
    • ESC Acute CardioVascular Care 2024
      Friday 08 March
      ESC event
      Athens - Greece

      The meeting place for all professionals dealing with patients in acute setting.

      08/03/2024 00:00 10/03/2024 00:00 Europe/Paris ESC Acute CardioVascular Care 2024

      Access event page

      Athens - Greece Association for Acute CardioVascular Care contact@escardio.org true DD/MM/YYYY
    • ESC Working Group on Cardiovascular Regenerative and Reparative Medicine
      Tuesday 12 March
      ESC event

      Nucleotide and in particular RNA-therapeutics are of increasing importance. With Inclisiran (PMID: 27959715), we have a first small interfering RNA (siRNA) therapeutic for the blocking of PCSK9 translation in clinical practice for lowing of LDL-cholesterol. More recently, CRISPR Cas9 encoding RNA with concomitant single guide RNA targeting misfolded transthyretin (TTR) has demonstrated clinical efficacy in patients with TTR amyloidosis (PMID: 34215024). Numerous RNA therapeutics will follow (PMID: 36329321; PMID: 33816449), riding also on the clinical experienced gained from modRNA development for COVID vaccination, because they are easy to develop and can be precisely targeted as highly specific therapies.

      12/03/2024 15:30 12/03/2024 16:30 Europe/Paris Working Group Talk "RNA-based therapies"

      Access event page

      ESC Working Group on Cardiovascular Regenerative and Reparative Medicine contact@escardio.org DD/MM/YYYY
    • Heart Failure Association of the ESC
      Wednesday 20 March
      Other event
      The leading meeting for basic and translational heart failure science in Europe.
      20/03/2024 13:00 21/03/2024 14:00 Europe/Paris HFA Winter Research Meeting on Translational Heart Failure Research

      Annual Winter Research Meeting

      Held in Les Diablerets, Switzerland, on 25-28 January 2017, this meeting covers aspects of Translational and Basic Science in heart failure

      Access event page

      Heart Failure Association of the ESC contact@escardio.org DD/MM/YYYY